{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:58:21Z","timestamp":1789016301261,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T00:00:00Z","timestamp":1503014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,11]]},"abstract":"Summary<\/jats:title>\n \n Ibrutinib is highly active in treating mantle cell lymphoma (\n MCL<\/jats:styled-content>\n ), an aggressive B\u2010cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed\/refractory\n MCL<\/jats:styled-content>\n (\n n<\/jats:italic>\n \u00a0=\u00a0370) treated with ibrutinib had an objective response rate (\n ORR<\/jats:styled-content>\n ) of 66% (20% complete response; 46% partial response); median duration of response (\n DOR<\/jats:styled-content>\n ), progression\u2010free survival (\n PFS<\/jats:styled-content>\n ) and overall survival (\n OS<\/jats:styled-content>\n ) were 18\u00b76, 12\u00b78 and 25\u00b70\u00a0months, respectively. Univariate analyses showed patients with one\n versus<\/jats:italic>\n >one prior line of therapy had longer\n OS<\/jats:styled-content>\n . Multivariate analyses identified that one prior line of therapy affected\n PFS<\/jats:styled-content>\n ; Eastern Cooperative Oncology Group (\n ECOG<\/jats:styled-content>\n ) performance status, simplified\n MCL<\/jats:styled-content>\n international prognostic index (\n sMIPI<\/jats:styled-content>\n ) score, bulky disease, and blastoid histology affected\n OS<\/jats:styled-content>\n and\n PFS<\/jats:styled-content>\n . Patients with blastoid\n versus<\/jats:italic>\n non\u2010blastoid histology had similar time to best response, but lower\n ORR<\/jats:styled-content>\n ,\n DOR<\/jats:styled-content>\n ,\n PFS<\/jats:styled-content>\n and\n OS<\/jats:styled-content>\n .\n OS<\/jats:styled-content>\n and\n PFS<\/jats:styled-content>\n were longer in patients with better\n sMIPI<\/jats:styled-content>\n , patients with\n ECOG<\/jats:styled-content>\n performance status 0\u20131, non\u2010bulky disease and non\u2010blastoid histology. Additionally, the proportion of patients with poor prognostic factors increased with increasing lines of therapy. Together, results suggest that patient outcomes following treatment failure with ibrutinib are related to the natural biological evolution of the disease.\n <\/jats:p>","DOI":"10.1111\/bjh.14870","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T08:16:36Z","timestamp":1503044196000},"page":"430-438","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open\u2010label studies"],"prefix":"10.1111","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Simon","family":"Rule","sequence":"first","affiliation":[{"name":"Plymouth University Medical School Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University Medical Center Hackensack NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"University Medical School of the Johannes Gutenberg University Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Auer","sequence":"additional","affiliation":[{"name":"St. Bartholomew's Hospital Barts Health NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Cavazos","sequence":"additional","affiliation":[{"name":"Pharmacyclics Sunnyvale CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Black","family":"Liu","sequence":"additional","affiliation":[{"name":"Janssen China Research & Development Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Janssen Research & Development Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fong","family":"Clow","sequence":"additional","affiliation":[{"name":"Pharmacyclics Sunnyvale CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna D.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Janssen Research & Development Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrin","family":"Beaupre","sequence":"additional","affiliation":[{"name":"Pharmacyclics Sunnyvale CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Janssen Research & Development Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wildgust","sequence":"additional","affiliation":[{"name":"Janssen Research & Development Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647834"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1094801"},{"key":"e_1_2_9_4_1","article-title":"Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE\u2122 trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma","author":"Brown J.","year":"2014","journal-title":"American Society of Hematology"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.664797"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24279"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt139"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.358"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V128.22.784.784","article-title":"Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo\u2010retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC network","volume":"128","author":"Choquet S.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2269-8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu264"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.2046","article-title":"Phase I study of single agent ibrutinib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma","volume":"34","author":"Grommes C.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200490"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-597914"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.V126.23.469.469","article-title":"Ibrutinib versus temsirolimus: results from a phase 3, international, randomized, open\u2010label, multicenter study in patients with previously treated mantle\u2010cell lymphoma","volume":"126","author":"Rule S.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00559-8"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood.V124.21.4471.4471","article-title":"Efficacy and safety of single\u2010agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy","volume":"124","author":"Wang M.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14870","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:29:36Z","timestamp":1695947376000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/bjh.14870"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14870","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,18]]},"assertion":[{"value":"2017-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}